K. Culos

American Society for Transplantation and Cellular Therapy Pharmacy Special Interest Group Position Statement on Pharmacy Practice Management and Clinical Management for COVID-19 in Hematopoietic Cell Transplantation and Cellular Therapy Patients in the United States

C. Timlin, Zahra Mahmoudjafari, Maurice D. Alexander, 2020, Biology of Blood and Marrow Transplantation.

Early viral reactivation despite excellent immune reconstitution following haploidentical Bone marrow transplant with post‐transplant cytoxan for sickle cell disease

Heidi Chen, A. Kassim, J. de la Fuente, 2019, Transplant infectious disease : an official journal of the Transplantation Society.

Chimeric Antigen Receptor T Cell Therapy: A Comprehensive Review of Clinical Efficacy, Toxicity, and Best Practices for Outpatient Administration.

Zahra Mahmoudjafari, Maurice D. Alexander, J. Roddy, 2021, Transplantation and cellular therapy.

The use of venetoclax‐based salvage therapy for post‐hematopoietic cell transplantation relapse of acute myeloid leukemia

R. Jayani, A. Kassim, B. Savani, 2020, American journal of hematology.

Salvage Therapy after Allogeneic Hematopoietic Cell Transplantation: Targeted and Low-Intensity Treatment Options in Myelodysplastic Syndrome and Acute Myeloid Leukemia

K. Culos, Michael T. Byrne, M. Byrne, 2019, Clinical hematology international.

Minimal residual disease negativity and lenalidomide maintenance therapy are associated with superior survival outcomes in multiple myeloma

A. Kassim, C. Mosse, R. Cornell, 2020, Bone Marrow Transplantation.

Melphalan 200 mg/m2 in patients with renal impairment is associated with increased short-term toxicity but improved response and longer treatment-free survival

D. Rondelli, K. Sweiss, P. Patel, 2016, Bone Marrow Transplantation.

Foiling fungal disease post hematopoietic cell transplant: review of prophylactic strategies

S. Rubinstein, B. Savani, K. Culos, 2018, Bone Marrow Transplantation.